C4 Therapeutics, Inc. Payments of Stock Issuance Costs
C4 Therapeutics, Inc. (CCCC) reported Payments of Stock Issuance Costs of $8.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-02-26
- C4 Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-06-30 was $11.30M.
- C4 Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2020-12-31 was $0.00.
- C4 Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2020-09-30 was $0.00.
- C4 Therapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $8.10M.
- C4 Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $11.30M, a 0.00% change from fiscal 2021.
- C4 Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $11.30M, a 151.11% increase from fiscal 2020.
- C4 Therapeutics, Inc. payments of stock issuance costs for fiscal 2020 was $4.50M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 9 month as first filed | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $8.10M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $11.30M 10-K · filed 2023-02-23 | ||||
| 2021-12-31 | $11.30M 10-K · filed 2023-02-23 | ||||
| 2021-06-30 | $11.30M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $4.50M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.50M 10-Q · filed 2021-11-10 | $4.47M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $4.50M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |